<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275170</url>
  </required_header>
  <id_info>
    <org_study_id>7655-005</org_study_id>
    <nct_id>NCT01275170</nct_id>
  </id_info>
  <brief_title>A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005 AM1)</brief_title>
  <official_title>A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part I of this study will compare the pharmacokinetics of MK-7655, dosed in combination with
      PRIMAXINÂ® (imipenem + cilastatin), in participants with impaired renal function and matched
      control participants. In Part II of the study, the potential for renal insufficiency to
      affect non-renal clearance mechanisms will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the curve of plasma concentration of drug against time (AUC) [0-infinity]after administration of MK-7655</measure>
    <time_frame>14 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of MK-7655 that is removed by hemodialysis</measure>
    <time_frame>Immediately prior to infusion on Day 1, and immediately after infusion on Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at the end of the infusion (C[EOI]) of MK-7655</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration occurs (Tmax) for MK-7655</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of MK-7655</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of MK-7655</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of MK-7655 dose excreted unchanged in urine</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma AUC[0-infinity] of probe substrates of cytochrome P450 enzymes (CYP) 1A2, 3A4,2 and C19 in participants with severe renal impairment versus healthy matched subjects</measure>
    <time_frame>From Hour 0 to Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma AUC[0-infinity] of probe substrates of cytochrome P450 enzymes (CYP) 1A2, 3A4,2 and C19 in participants with end stage renal disease (ESRD), before and after hemodialysis, versus healthy matched subjects</measure>
    <time_frame>From Hour 0 to Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AUC[0-infinity] of imipenem</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma C[EOI] of imipenem</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Tmax of imipenem</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of imipenem</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of imipenem</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of imipenem dose excreted unchanged in urine</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AUC[0-infinity] of cilastatin</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma C[EOI] of cilastatin</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Tmax of cilastatin</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of cilastatin</measure>
    <time_frame>14 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of cilastatin</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of cilastatin dose excreted unchanged in urine</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Prior to first dose through 14 days after last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Infectious Disease</condition>
  <arm_group>
    <arm_group_label>Panel A Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will not participate in Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will not participate in Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will not participate in Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will not participate in Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel E participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel F participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel G End Stage Renal Disease with Dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel G participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study, during both Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel H participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-7655</intervention_name>
    <description>125 mg intravenous (IV) over 30 minutes as a single dose</description>
    <arm_group_label>Panel A Mild Renal Impairment</arm_group_label>
    <arm_group_label>Panel B Healthy Participants</arm_group_label>
    <arm_group_label>Panel C Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Panel D Healthy Participants</arm_group_label>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Dialysis</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imipenem + cilastatin</intervention_name>
    <description>250 mg IV over 30 minutes as a single dose</description>
    <arm_group_label>Panel A Mild Renal Impairment</arm_group_label>
    <arm_group_label>Panel B Healthy Participants</arm_group_label>
    <arm_group_label>Panel C Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Panel D Healthy Participants</arm_group_label>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Dialysis</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <other_name>PRIMAXINÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>caffeine caplet, single 200 mg dose, orally</description>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Dialysis</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
    <other_name>No DozÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>midazolam hcl syrup, single 2.0 mg dose, orally</description>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Dialysis</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally</description>
    <arm_group_label>Panel E Severe Renal Impairment</arm_group_label>
    <arm_group_label>Panel F Healthy Participants</arm_group_label>
    <arm_group_label>Panel G End Stage Renal Disease with Dialysis</arm_group_label>
    <arm_group_label>Panel H Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Participants of reproductive potential (male or female) must be willing to use
             contraception.

          -  Body Mass Index (BMI) â¤40 kg/m^2

          -  Weight &gt;60 kg at screening visit

          -  No clinically significant abnormality on electrocardiogram (ECG) at screening visit
             and/or prior to administration of the initial dose of study drug

          -  Panels A-D: smokers will be limited to no more that 10 cigarettes per day.

          -  Panels E-H: nonsmoker or has not used nicotine for at least 6 months

          -  In good health (stable health for participants with renal impairment)

        Exclusion criteria

          -  Pregnant or breastfeeding.

          -  History of recent stroke, chronic seizures, or major neurological disorder

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, immunological, respiratory, or genitourinary abnormalities or diseases

          -  History of malignant neoplastic disease. Exceptions: (1) adequately treated
             non-melanomatous skin carcinoma or carcinoma in situ of the cervix; (2) other
             malignancies that have been successfully treated â¥10 years prior to the screening
             visit

          -  Panels A-D: Use of any medication (prescription or non-prescription) or herbal
             remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2
             weeks (or 5 half-lives) prior to administration of the initial dose of study drug to
             the post study visit

          -  Panels E-H: Use of any medication (prescription or non-prescription) or herbal
             remedies (such as St. John's Wort [Hypericum perforatum]) that are inhibitors or
             inducers of CYP1A2, CYP2C19, CYP34A, or substrates of CYP2C19, beginning approximately
             2 weeks (or 5 half-lives) prior to administration of the probe cocktail, until the
             post-study visit

          -  Consumption of greater than 3 glasses of alcoholic beverages (1 glass is approximately
             equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits
             [25 mL/1 ounce]) per day

          -  Consumption of greater than 6 servings (1 serving is approximately equivalent to 120
             mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day

          -  Major surgery, donation or loss of 1 unit of blood (approximately 500 mL), or
             participation in another investigational study within 4 weeks prior to the screening
             visit

          -  History of multiple and/or severe allergies (including latex allergy), or prior
             anaphylactic reaction or intolerability to prescription or non-prescription drugs or
             food

          -  History of hypersensitivity to PRIMAXINÂ® IV or other beta lactam antibiotic (including
             but not limited to penicillins, cephalosporins, monobactams and carbapenems)

          -  Regular user (including recreational use of drugs [including alcohol]) within
             approximately 12 months of screening visit

          -  History of kidney removal and/or renal transplant

          -  History of Clostridium difficile colitis or known C. difficile colonization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
    <mesh_term>MK-7655</mesh_term>
    <mesh_term>Imipenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

